MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
On May 10, 2022, MaxCyte, Inc. (NASDAQ: MXCT) granted stock options for 73,700 shares to six newly hired employees as part of their 2021 Inducement Plan. The options have a ten-year term with an exercise price of $4.81 per share, equal to the stock's closing price on the grant date. These options will vest over four years, with 25% vesting after 12 months, subject to continued employment. MaxCyte focuses on cell-engineering technologies to support cell-based research and therapies, leveraging its proprietary Flow Electroporation platform.
- Granting of 73,700 stock options indicates potential for employee motivation and retention.
- The exercise price of $4.81 aligns with the market price, indicating fair compensation.
- None.
GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that, on May 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 73,700 shares of MaxCyte’s common stock to six (6) newly hired employees. The stock options were granted as material inducements to employment with MaxCyte in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the MaxCyte, Inc. 2021 Inducement Plan (the “2021 Inducement Plan”).
The stock options have a ten-year term and an exercise price of
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
| US IR Adviser Gilmartin Group David Deuchler, CFA | +1 415-937-5400 ir@maxcyte.com |
| Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden | +44 (0)20 7886 2500 |
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh | +44 (0)203 709 5700 maxcyte@consilium-comms.com |
FAQ
What stock options did MaxCyte grant on May 10, 2022?
What is the exercise price of the stock options granted by MaxCyte?
What is the vesting schedule for the stock options at MaxCyte?
Why were the stock options granted to employees at MaxCyte?
